Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 20/20 | 0.67 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.67 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.67 |
| ▸ | CLK2 | P49760 | 5/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1867721 | 0.89 | CLK1 (0.68) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL1098993 | 0.87 | HDAC1 (0.56) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL31207841 | 0.87 | HDAC1 (0.56) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL3810348 | 0.86 | CLK1 (0.51) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL30805945 | 0.85 | CLK1 (0.57) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL15697592 | 0.85 | CLK1 (0.57) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL1391285 | 0.85 | CLK1 (0.60) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL7340422 | 0.84 | CLK1 (0.67) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL19756734 | 0.84 | CLK1 (0.67) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL2895953 | 0.82 | MEN1 (0.64) | CLK1DYRK1ADYRK1BCLK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| EP-2403843-B1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | LIFE TECHNOLOGIES CORP (US) | 2018-11-07 | — | — | EP | disclosed |
| EP-3004057-B1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS | C&C RES LAB (KR) | 2018-07-25 | — | — | EP | disclosed |
| US-9955689-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9894901-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-02-20 | — | — | US | disclosed |
| US-9856508-B2 | Chemiluminescent compositions, methods, assays and kits for oxidative enzymes | Life Technologies Corporation (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856508-B2 | Chemiluminescent compositions, methods, assays and kits for oxidative enzymes | Life Technologies Corporation (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170137862-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | Life Technologies Corporation | 2017-05-18 | — | — | US | disclosed |
| US-20170137862-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | Life Technologies Corporation | 2017-05-18 | — | — | US | disclosed |
| US-20170137862-A1 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | Life Technologies Corporation | 2017-05-18 | — | — | US | disclosed |
| WO-2010101839-A2 | CHEMILUMINESCENT COMPOSITIONS, METHODS, ASSAYS AND KITS FOR OXIDATIVE ENZYMES | Life Technologies Corporation (US) | 2010-09-10 | — | — | WO | disclosed |
| EP-2183237-A1 | BENZOFURAN- AND BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AND USE THEREOF AS HISTAMINE 3 RECEPTOR MODULATORS | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20100076065-A1 | VITAMIN D RECEPTOR MODULATORS | LU JIANLIANG | 2010-03-25 | — | — | US | disclosed |
| US-7582775-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7534788-B2 | Benzofuran and benzothiophene-2-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | disclosed |
| EP-2049200-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MethylGene Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009013195-A1 | BENZOFURAN- AND BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AND USE THEREOF AS HISTAMINE 3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-20090029976-A1 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008073142-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076065-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP2R1, CYP24A1 | CLK1 3697/4885DYRK1A 2461/4885DYRK1B 2408/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | CLK1 3697/4885DYRK1A 2461/4885DYRK1B 2408/4885 |
| US-20090029976-A1 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES | HCAR2, HCAR1, HRH3 | CLK1 4628/4885DYRK1A 2333/4885DYRK1B 2999/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | CLK1 2856/4885DYRK1A 2468/4885DYRK1B 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.